Drug intelligence / Profile preview

Anti-CMV mAb

Development stage: Preclinical
Lead developer: Techinvention Lifecare
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Anti-CMV mAb is a monoclonal antibody being developed by Techinvention Lifecare for the treatment and prevention of Cytomegalovirus (CMV) infections. Discovered using phage display technology, the antibody is designed to bind and neutralize the virus. As of early 2024, the program is in the proof-of-concept stage of development, focusing on establishing efficacy and safety profiles in preclinical models to address infections caused by this common herpesvirus, which can be particularly severe in immunocompromised individuals and neonates.

Other names: anti-cytomegalovirus monoclonal antibody

Beyond the preview

Go deeper on Anti-CMV mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-CMV mAb.

Explore the full profile